CLINICAL OUTCOMES Mo.Ma™ Ultra Proximal Cerebral Protection Device

ARMOUR Trial 30-Day All Stroke Rate of 2.3%

The Mo.Ma™ Ultra proximal cerebral protection device was evaluated in the ARMOUR Trial,¹ a multicenter clinical study, during carotid artery stenting of a total of 262 high surgical risk patients with critical artery stenosis. The ARMOUR Trial primary endpoint (MACCE) was a composite endpoint of any myocardial infarction, stroke or death at 30 days post-procedure. The primary endpoint analysis was based upon 220 evaluable intent‑to‑treat patients (ITT).

ARMOUR TRIAL 30-DAY PRIMARY ENDPOINT

304-day event rates 220 patients (ITT).